Looking at the types of damages being awarded in trademark cases and how they’re being awarded, it’s highly likely that most damages awarded in these cases might never be recovered. “You can see it as two separate worlds of trademark cases,” Howard said. “There are cases in which a defendant doesn’t show up and it goes straight to default judgment, and then there’s everything else.” $4.6 billion dollars, or 84.6 percent of all damages awarded in district court trademark cases going back to 2009, have been awarded on default judgment.
Novartis has agreed to acquire French radiopharmaceutical firm Advanced Accelerator Applications (AAA) in a deal which values AAA at $3.9 billion USD. The deal, funded through short- and long-term debt, adds the radioligand therapy (RDL) known as Lutathera to the Novartis pipeline. This drug, approved for use in the European Union and currently undergoing trials for approval by the U.S. Food and Drug Administration (FDA), is used in the treatment of patients suffering from neuroendocrine tumors.
The United States Patent and Trademark Office would be exempt from turning over its collected fees to the Treasury. The USPTO, however, would be required no later than March 1 of each year to submit to Congress a report that describes any fee, fine, penalty, or proceeds from a settlement collected by the Office for the previous fiscal year. So why is the USPTO specifically excluded from this particular government wide agency fee diversion? That is a very good question.